Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 83
13
Diseases
9
Unique genes
0.422
Avg. similarity score
Achondroplasia
Most-connected disease (12 links)
Disease
Searched: Myeloma
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Myeloma
Achondroplasia
Camptodactyly, tall stature, and hearing loss syndrome
Catshl syndrome
Crouzon syndrome with acanthosis nigricans
Muenke syndrome
Cheilitis
Flat urothelial hyperplasia
Hypochondroplasia
Keratinocytic nonepidermolytic nevus
Severe achondroplasia-developmental delay-acanthosis nigricans syndrome
Thanatophoric dysplasia
Ureter urothelial carcinoma
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Achondroplasia | 12 | 12 | 1 |
| Camptodactyly, tall stature, and hearing loss syndrome | 12 | 12 | 1 |
| Catshl syndrome | 12 | 12 | 1 |
| Crouzon syndrome with acanthosis nigricans | 11 | 11 | 1 |
| Muenke syndrome | 10 | 10 | 1 |
| Cheilitis | 5 | 5 | 3 |
| Flat urothelial hyperplasia | 5 | 5 | 1 |
| Hypochondroplasia | 5 | 5 | 1 |
| Keratinocytic nonepidermolytic nevus | 5 | 5 | 2 |
| Severe achondroplasia-developmental delay-acanthosis nigricans syndrome | 5 | 5 | 1 |
| Thanatophoric dysplasia | 5 | 5 | 1 |
| Ureter urothelial carcinoma | 5 | 5 | 4 |
| Myeloma | 4 | 4 | 5 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| FGFR3 | 13 / 13 | Achondroplasia, Camptodactyly, tall stature, and hearing loss syndrome, Catshl syndrome, Cheilitis and 9 more |
| NRAS | 2 / 13 | Keratinocytic nonepidermolytic nevus, Myeloma |
| TP53 | 2 / 13 | Cheilitis, Ureter urothelial carcinoma |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Bladder cancer | KEGG | 5 / 41 | 163× | 4.49e-11 | 5.82e-9 ✓ sig. |
| Thyroid cancer | KEGG | 4 / 37 | 144× | 9.50e-9 | 7.05e-7 ✓ sig. |
| Hepatocellular carcinoma | KEGG | 5 / 170 | 39.2× | 6.45e-8 | 3.80e-6 ✓ sig. |
| Endometrial cancer | KEGG | 4 / 59 | 90.5× | 6.50e-8 | 3.83e-6 ✓ sig. |
| Central carbon metabolism in cancer | KEGG | 4 / 71 | 75.2× | 1.38e-7 | 7.42e-6 ✓ sig. |
| Chronic myeloid leukemia | KEGG | 4 / 77 | 69.3× | 1.92e-7 | 9.89e-6 ✓ sig. |
| Colorectal cancer | KEGG | 4 / 87 | 61.4× | 3.15e-7 | 1.53e-5 ✓ sig. |
| MAPK signaling pathway | KEGG | 5 / 299 | 22.3× | 1.07e-6 | 4.44e-5 ✓ sig. |
| Breast cancer | KEGG | 4 / 148 | 36.1× | 2.66e-6 | 9.66e-5 ✓ sig. |
| PI3K-Akt signaling pathway | KEGG | 5 / 361 | 18.5× | 2.72e-6 | 9.84e-5 ✓ sig. |
| Gastric cancer | KEGG | 4 / 150 | 35.6× | 2.81e-6 | 1.01e-4 ✓ sig. |
| Hepatitis C | KEGG | 4 / 159 | 33.6× | 3.54e-6 | 1.23e-4 ✓ sig. |
| Hepatitis B | KEGG | 4 / 163 | 32.7× | 3.91e-6 | 1.34e-4 ✓ sig. |
| Proteoglycans in cancer | KEGG | 4 / 204 | 26.2× | 9.53e-6 | 2.80e-4 ✓ sig. |
| Acute myeloid leukemia | KEGG | 3 / 68 | 58.9× | 1.42e-5 | 3.91e-4 ✓ sig. |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| MAPK cascade | GO:0000165 | 4 / 147 | 56.5× | 4.49e-7 | 4.44e-5 ✓ sig. |
| cellular response to xenobiotic stimulus | GO:0071466 | 3 / 65 | 95.8× | 3.32e-6 | 2.28e-4 ✓ sig. |
| intrinsic apoptotic signaling pathway by p53 class mediator | GO:0072332 | 2 / 29 | 143× | 8.32e-5 | 2.70e-3 ✓ sig. |
| positive regulation of axonogenesis | GO:0050772 | 2 / 30 | 138× | 8.91e-5 | 2.84e-3 ✓ sig. |
| negative regulation of fibroblast proliferation | GO:0048147 | 2 / 35 | 119× | 1.22e-4 | 3.56e-3 ✓ sig. |
| T cell differentiation in thymus | GO:0033077 | 2 / 41 | 101× | 1.67e-4 | 4.47e-3 ✓ sig. |
| transcription initiation-coupled chromatin remodeling | GO:0045815 | 2 / 41 | 101× | 1.67e-4 | 4.47e-3 ✓ sig. |
| cell population proliferation | GO:0008283 | 3 / 263 | 23.7× | 2.17e-4 | 5.38e-3 ✓ sig. |
| response to ionizing radiation | GO:0010212 | 2 / 47 | 88.4× | 2.20e-4 | 5.43e-3 ✓ sig. |
| chromosome organization | GO:0051276 | 2 / 51 | 81.4× | 2.60e-4 | 6.12e-3 ✓ sig. |
| ERK1 and ERK2 cascade | GO:0070371 | 2 / 55 | 75.5× | 3.02e-4 | 6.82e-3 ✓ sig. |
| cellular response to UV | GO:0034644 | 2 / 55 | 75.5× | 3.02e-4 | 6.82e-3 ✓ sig. |
| positive regulation of miRNA transcription | GO:1902895 | 2 / 56 | 74.2× | 3.13e-4 | 7.00e-3 ✓ sig. |
| negative regulation of developmental growth | GO:0048640 | 1 / 1 | 2,076× | 4.82e-4 | 9.24e-3 ✓ sig. |
| negative regulation of helicase activity | GO:0051097 | 1 / 1 | 2,076× | 4.82e-4 | 9.24e-3 ✓ sig. |